Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today key updates from the International Surgical Sleep Society (ISSS) and American Academy of Otolaryngology (AAO-HNSF) meetings which took place in Philadelphia September 9-14th.
MINNEAPOLIS, Sept. 14, 2022 (GLOBE NEWSWIRE) --Inspire Medical Systems Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today key updates from the International Surgical Sleep Society (ISSS) and American Academy of Otolaryngology (AAO-HNSF) meetings which took place in Philadelphia September 9-14th.
“We were excited to return to in-person conferences and highlight our recent innovative technology enhancements to the Inspire platform and share compelling clinical data further demonstrating the real-world efficacy of our treatment,” said Tim Herbert, President and CEO. “Inspire is a proud partner and sponsor of ISSS, the world’s preeminent organization dedicated to the surgical evaluation and treatment of patients with sleep disorders, and AAO-HNSF, one of the world’s largest organizations representing specialists who treat the ear, nose, throat, and related structures of the head and neck.”
At the Inspire booth, physicians reviewed the Inspire procedure using new 3D visualization software and received updates on technology enhancements across the entire Inspire portfolio, including full-body MRI labeling, new lead technology designed for the less invasive 2-incision procedure, and the new Inspire SleepSync™ remote patient management platform.
In the scientific sessions, Inspire was featured prominently throughout the meetings, with over 30 oral abstracts and posters presented by leading otolaryngologists and sleep surgeons.
Posters and Presentations
- A Noninferiority Analysis of 3- versus 2- Incision Techniques for HNS Implantation. (David T. Kent, MD et al.)
- Safety and efficacy profile for 2-incision technique is noninferior to 3-incision technique
- Operative time is significantly decreased with the 2-incision technique to 87 minutes
- Real-World Outcomes from Over 3 Million Nights of Upper Airway Stimulation Therapy for CPAP Intolerant Obstructive Sleep Apnea. (Jordan S. Weiner, MD et al.)
- First ever “big data” report of UAS outcomes
- Usage trends demonstrate high compliance to UAS despite history of CPAP intolerance
- Outcomes of Surgical Upper Airway Stimulation in Hispanic vs Non-Hispanic Populations. (Linda C. Magana, MD, Ryan J. Soose, MD, et al., on behalf of the ADHERE Registry investigators)
- Analysis demonstrated no difference in UAS outcomes (e.g. AHI, ESS, objective usage, and usage rates) in Hispanic patients versus non-Hispanic patients
- The number of Hispanic participants in the ADHERE registry is just 2.1% of the overall participants, which is significantly lower than their proportion in the general U.S. population (18.7%)
- This analysis highlights the need to understand barriers to care in receiving surgical UAS for patients of differing socioeconomic, ethnic, and educational backgrounds
- Long-term Generator Replacement in Hypoglossal Nerve Stimulator Clinical Trial Patients. (Ryan J. Soose, MD et al.)
- Longest follow-up study of hypoglossal nerve stimulation
- IPG replacements are safe and typically occur without complications
- Outcomes (AHI, therapy usage) at 9 years are consistent with 5-year results
About ISSS
The ISSS is the world’s preeminent organization dedicated to the surgical evaluation and treatment of patients with sleep disorders. For more information, please visit www.surgicalsleep.org.
About AAO-HNSF
The AAO-HNS (“the Academy”) is one of the world’s largest organizations representing specialists who treat the ear, nose, throat, and related structures of the head and neck. Head and neck surgeons diagnose and treat medical disorders that are among the most common affecting patients of all ages in the United States and around the world. Those medical conditions include chronic ear disease, hearing and balance disorders, hearing loss, sinusitis, snoring and sleep apnea, allergies, swallowing disorders, nosebleeds, hoarseness, dizziness, and tumors of the head and neck as well as intricate micro-surgical procedures of the head and neck. The Academy represents approximately 13,000 ENT surgeons. For more information, please visit www.entnet.org.
About Inspire Medical Systems
Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.
For additional information about Inspire, please visit www.inspiresleep.com.
Safe Harbor for Forward-Looking Statements
This press release may contain forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and important factors could cause actual results to differ materially from those anticipated, including the factors identified under the captions “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, and as such factors may be updated from time to time in our other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov and the Investors page of our website at www.inspiresleep.com.
Investor and Media Contact:
Ezgi Yagci
Vice President, Investor Relations
ezgiyagci@inspiresleep.com
617-549-2443
